ADM Tronics Unlimited, Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Andre' DiMino
- Full Time Employees
- 30
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 224 Pegasus Avenue Northvale NJ United States of America 07647
- IPO Date
- Jul 19, 1990
- CIK
- 0000849401
- Website
- admtronics.com
- Similar Companies
- Business
- ADM Tronics Unlimited, Inc. (ADMT) develops, manufactures and sells electronics for non-invasive medical applications and other technologies through its subsidiaries. The company operates in three segments: Electronics, providing proprietary non-invasive electrotherapy medical devices including the Aurex-3 tinnitus treatment system, Sonotron pain therapy device, Tinnitus Shield hearing protection, and Alvio respiratory therapy platform; Chemical, offering eco-friendly water-based formulations such as primers, adhesives, coatings and additives under Aqua Based Technologies and antistatic products including StaticPaint under Antistatic Industries, as well as Pros-Aide adhesive for medical prosthetics and special effects; and Engineering, delivering research, development, regulatory and contract manufacturing services for medical devices and electronics. Incorporated in 1969 and headquartered in Northvale, New Jersey, ADM Tronics conducts operations in the United States, Australia, Asia and Europe, targeting medical, veterinary, packaging, pharmaceutical and electronics industries. In recent developments, the company completes production of its Vet-Sonotron device for veterinary musculoskeletal pain treatment and launches distribution efforts for small animal and equine markets while advancing a human medical Sonotron version toward FDA 510(k) submission. ADM Tronics re-engineers the Aurex-3 device with digital, wireless and cloud features for enhanced tinnitus therapy and pursues FDA clearance for the upgraded model. It maintains a development partnership with QoL Devices, Inc. for the Alvio respiratory platform and collaborates with Otifleks on the patent-pending Tinnitus Shield, reporting revenue growth and improved gross margins in fiscal 2025.
Comparing OPKO Health (NASDAQ:OPK) & ADM Tronics Unlimited (OTCMKTS:ADMT)
Reviewing ADM Tronics Unlimited (OTCMKTS:ADMT) & Spectral AI (NASDAQ:MDAI)
ADM Tronics Unlimited (OTCMKTS:ADMT) Short Interest Down 12.4% in January
ADM Tronics Reports Third Quarter of Fiscal Year 2026 Results
ADM Tronics Reports Second Quarter of Fiscal Year 2026 Results
ADM Tronics Reports First Quarter of Fiscal Year 2026 Results
ADM Tronics Reports Fiscal Year 2025
ADM Tronics Reports Second Quarter of Fiscal Year 2025 Results
ADM Tronics Reports First Quarter of Fiscal Year 2025 Results
ADM Tronics Reports Fiscal Year 2024
ADM Tronics Shareholder Video Conference Replay Available Now for Viewing Online with Update on Vet-Sonotron Veterinary Pain Treatment Technology
ADM Tronics to Host Shareholder Video Call on March 27 to Update Launch and Significance of Vet-Sonotron Veterinary Pain Treatment Device
ADM Tronics' Vet-Sonotron(R) Veterinary Pain Treatment Device Now in Production and Already Receiving Pre-Orders
Novel Therapeutic Technology Developed & Manufactured by ADM Tronics for Origin Life Sciences to Begin Clinical Study on Onychomycosis
ADM Tronics Prepares for Commercial Launch of Vet-Sonotron(R) Veterinary Therapy Device
ADM Tronics Reports Second Quarter of Fiscal Year 2024 Results
ADM Tronics Reports First Quarter of Fiscal Year 2024 Results
ADM Tronics Reports Fiscal Year 2023
Adamant signs Letter of Intent to acquire 51% Interest in Europronet
ADM Tronics Receives First Place in the Category of Electronics at the 2021 Go Global Awards